Synthesis of photoreactive phosphatidic acid analogues displaying activatory properties on cyclic AMP-phosphodiesterases. Photoaffinity labeling of an isoform of phosphodiesterase

Journal of Medicinal Chemistry

Volumn 45, Issue 8, 2002, Pages 1678-1685

  Picq, Madeleine ^a   Huang, Yan ^b   Lagarde, Michel ^a   Doutheau, Alain ^c   Nemoz, Georges ^a  

^a INSERM   (France)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 O [12 [N (4 AZIDO 2,3,5,6 TETRAFLUOROBENZOYL)]AMINODODECANOYL] 2 O OLEOYLGLYCERO 3 PHOSPHATE; 1 O OLEOYL 2 O [12 [N (AZIDO 2,3,5,6 TETRAFLUOROBENZOYL)]AMINODODECANOYL]GLYCERO 3 PHOSPHATE; 1 O PALMITOYL 2 O [12 [N (4 AZIDO 2,3,5,6 TETRAFLUOROBENZOYL)]AMINODODECANOYL]GLYCERO 3 PHOSPHATE; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; ISOENZYME; PHOSPHATIDIC ACID; PHOSPHODIESTERASE IV; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PHOSPHOLIPID; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ARTICLE; COVALENT BOND; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME BINDING; LIPOLYSIS; NONHUMAN; PHOTOAFFINITY LABELING; PHOTOREACTIVITY; SIGNAL TRANSDUCTION; ULTRAVIOLET IRRADIATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACYLATION; AZIDES; BINDING SITES; CATALYSIS; HYDROLYSIS; ISOENZYMES; PHOSPHATIDIC ACIDS; PHOSPHOLIPASE D; PHOSPHOLIPASES A; PHOSPHOLIPIDS; PHOTOAFFINITY LABELS; RECOMBINANT PROTEINS; ULTRAVIOLET RAYS;

EID: 0037061598     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011032f     Document Type: Article

References (41)

1. Recent progress in understanding the hormonal regulation of phosphodiesterases
2. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3 kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes
3. Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells
4. Short-term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation
5. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis
6. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice
7. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
8. Phosphodiesterases: The journey towards therapeutics
9. Additive effects of phosphodiesterase-4 inhibition on effects of SP-C surfactant
10. Selective activation of rolipram-sensitive cAMP-specific phosphodiesterase isoforms by phosphatidic acid
11. Phosphatidic acid: A lipid messenger involved in intracellular and extracellular signalling
12. Phosphatidic acid generation through interleukin 2 (IL-2)-induced alpha-diacylglycerol kinase activation is an essential step in IL-2-mediated lymphocyte proliferation
13. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding
14. Relationships between phosphatidic acid and cyclic nucleotide phosphodiesterases in activated human blood mononuclear cells
15. Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C
16. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid
17. Phosphatidic acid activation of protein kinase C-zeta overexpressed in COS cells: Comparison with other protein kinase C isotypes and other acidic lipids
18. Phospholipase C-delta3 binds with high specificity to phosphatidylinositol 4,5-bisphosphate and phosphatidic acid in bilayer membranes
19. Regulation of PDE-4cAMP phosphodiesterases by phosphatidic acid
20. New reagents for photoaffinity labeling synthesis and photolysis of functionalized perfluorophenyl azides
21. Chain-substituted lipids in monolayer films. A study of molecular packing
22. Attenuation of cAMP-mediated responses in MA-10 leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase
23. Characterization of the structure of a low km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain
24. Multiple cyclic nucleotide phophodiesterase activities from rat brain
25. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase
26. Synthesis and properties of photoactivable phospholipid derivatives designed to probe the membrane-associate domain of proteins
27. Photolabelling of membrane proteins with photoactive phospholipids
28. Bilayer/cytoskeleton interactions in lipid-symmetric erythrocytes assessed by a photoactivable phospholipid analogue
29. Planar bilayer membranes from photoactivable phospholipids
30. Identification of a putative membrane receptor for the bioactive phospholipid lysophosphatidic acid
31. Human erythrocyte band 7.2b is preferentially labeled by a photoreactive phospholipid
32. Phosphoinosotide binding specificity among phospholipase C isozymes as determined by photo-cross-linking to novel substrate and product analogs
33. Use of photoactivable analogues to monitor lipid transport in mammalian cells
34. Selective stimulation of a cAMP-specific phosphodiesterase (PDE4A5) isoform by phosphatidic acid molecular species endogenously formed in rat thymocytes
35. Photochemistry of fluorinated aryl azides in toluene solution and in frozen polycrystals
36. Synthesis of tetrafluoro-substituted aryl azides and its protio analogues as photolabeling affinity reagents for the estrogen receptor
37. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat
38. 4-Dialkylaminopyridines as highly active acylation catalysts
39. Glycerophospholipid synthesis: Improved general methods and new analogs containing photoactivable groups
40. Mixed-chain phosphatidylcholine analogues modified in the choline moiety: Preparation of isomerically pure phospholipids with bulky head groups and one acyl chain twice as long as the other
41. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?